Anti-inflammatory drugs may shorten the recovery time of COVID19 patients.

September 16, 2020 /--- -- Lilly Pharmaceuticals Inc. said it will shorten its recovery time by adding anti-inflammatory drugs to drugs in hospitalized COVID-19 patients.
the study was sponsored by the U.S. National Institute of Allergy and Infectious Diseases and involved 1,000 people.
results have not yet been published or reviewed by independent scientists, but the government has confirmed that Lilly's statement is accurate.
(Photo: Darron Cummings) The study tested a pill called baricitinib, which Lilly has commercialized to treat rheumatoid arthritis.
it is well known that overactive immune systems can also cause serious problems in patients with coronaviruses, Lilly wants to test the effects of the anti-inflammatory drug on COVID19 patients.
study participants were treated with remdesivir, a drug previously shown to shorten recovery time.
lilly company said that people who received baricitinib treatment at the same time had a one-day shorter recovery time than those who received only remdesivir treatment.
said it plans to discuss with regulators the possibility of emergency use of Baricitinib in hospitalized COVID-19 patients.
if approved, Lilly will recommend the sale of the drug through normal commercial means.
, at current prices, the government will pay $105 a day for each patient, while for those with private insurance, the hospital will pay about $150 a day.
former U.S. Food and Drug Administration Dr. Jesse Goodman said it's important to know how many study participants have also taken steroid drugs, which has been shown in other studies to reduce the risk of death in patients hospitalized with COVID-19.
(bioon.com) Source: Anti-ingy drug may shorten COVID-19 recovery time.